Inventor
WU YUSHENG
CN49 patents
⚠️ This page may combine multiple inventors who share the name “WU YUSHENG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
12 patentsUS6329395B1Dec 11, 2001
Neuropeptide Y5 receptor antagonists
SCHERING CORP186 citations99
US7763609B2Jul 27, 2010
Heterocyclic aspartyl protease inhibitors
SCHERING CORP38 citations95
US6894063B2May 17, 2005
Substituted urea neuropeptide Y Y5 Receptor antagonists
SCHERING CORP24 citations93
US7592348B2Sep 22, 2009
Heterocyclic aspartyl protease inhibitors
SCHERING CORP16 citations92
US7700603B2Apr 20, 2010
Heterocyclic aspartyl protease inhibitors
SCHERING CORP9 citations84
US7662816B2Feb 16, 2010
Cyclic amine BACE-1 inhibitors having a benzamide substituent
SCHERING CORP11 citations84
US6946476B2Sep 20, 2005
Heteroaryl urea neuropeptide Y Y5 receptor antagonists
SCHERING CORP16 citations83
US7973067B2Jul 5, 2011
Heterocyclic aspartyl protease inhibitors
SCHERING CORP6 citations73
US6982267B2Jan 3, 2006
Heteroaryl urea neuropeptide Y Y5 receptor antagonists
SCHERING CORP9 citations73
US7598250B2Oct 6, 2009
Cyclic amine BACE-1 inhibitors having a heterocyclic substituent
SCHERING CORP5 citations62
US7309704B2Dec 18, 2007
Heteroaryl urea neuropeptide Y Y5 receptor antagonists
SCHERING CORP2 citations62
US7157472B2Jan 2, 2007
Neuropeptide Y Y5 receptor antagonists
SCHERING CORP0 citations42
ZHU ZHAONING
6 patentsUS8691831B2Apr 8, 2014
Heterocyclic aspartyl protease inhibitors
ZHU ZHAONING7 citations83
US8829036B2Sep 9, 2014
Heterocyclic aspartyl protease inhibitors
ZHU ZHAONING7 citations82
US8691833B2Apr 8, 2014
Heterocyclic aspartyl protease inhibitors
ZHU ZHAONING7 citations82
US8242112B2Aug 14, 2012
Heterocyclic aspartyl protease inhibitors
ZHU ZHAONING2 citations62
US8178513B2May 15, 2012
Heterocyclic aspartyl protease inhibitors
ZHU ZHAONING1 citations62
US8778980B2Jul 15, 2014
Heterocyclic aspartyl protease inhibitors
ZHU ZHAONING0 citations51
RIB X PHARMACEUTICALS INC
5 patentsUS6969726B2Nov 29, 2005
Biaryl heterocyclic compounds and methods of making and using the same
RIB X PHARMACEUTICALS INC44 citations95
US7148219B2Dec 12, 2006
Biaryl heterocyclic compounds and methods of making and using the same
RIB X PHARMACEUTICALS INC28 citations92
US7129259B2Oct 31, 2006
Halogenated biaryl heterocyclic compounds and methods of making and using the same
RIB X PHARMACEUTICALS INC31 citations92
US7705026B2Apr 27, 2010
Biaryl heterocyclic compounds and methods of making and using the same
RIB X PHARMACEUTICALS INC5 citations73
US7456206B2Nov 25, 2008
Biaryl heterocyclic compounds and methods of making and using the same
RIB X PHARMACEUTICALS INC8 citations73
WU YUSHENG
4 patentsUS8168641B2May 1, 2012
Aspartyl protease inhibitors
WU YUSHENG2 citations60
US8895741B2Nov 25, 2014
Process for the synthesis of biaryl oxazolidinones
WU YUSHENG0 citations50
US8629155B2Jan 14, 2014
Aspartyl protease inhibitors
WU YUSHENG1 citations50
US8324398B2Dec 4, 2012
Process for the synthesis of biaryl oxazolidinones
WU YUSHENG0 citations50
TYK MEDICINES INC
3 patentsUS10882845B2Jan 5, 2021
Crystal form of deuterated AZD9291, preparation method therefor, and use thereof
TYK MEDICINES INC0 citations53
US12435089B2Oct 7, 2025
3-oxadiazolyl substituted pyrazolo[1,5,a]pyrimidines for ROS1, NTRK, and ALK mediated diseases
TYK MEDICINES INC0 citations44
US12545681B2Feb 10, 2026
Compound used as RET kinase inhibitor and application thereof
TYK MEDICINES INC0 citations43
MELINTA THERAPEUTICS INC
3 patentsUS9550783B2Jan 24, 2017
Biaryl heterocyclic compounds and methods of making and using the same
MELINTA THERAPEUTICS INC0 citations51
US9376400B2Jun 28, 2016
Process for the synthesis of triazoles
MELINTA THERAPEUTICS INC0 citations51
US8796465B2Aug 5, 2014
Process for the syntheses of triazoles
MELINTA THERAPEUTICS INC1 citations51